Although the molecular expression of CD34 and BRAFV600E mutation could frequently and exclusively occur in GNT with epilepsy, their clinicopathological features were not yet well defined, as well as the prediction of long-term seizure outcome and tumor recurrence or progression3,5,6,16,17. This evidence concerns the gene CD34 and epilepsy.